One week after the AAD meeting, Christopher J. Sayed, MD, reflects on the lessons learned about hidradenitis suppurativa (HS) and the evolving approach to patient care. A key takeaway is the shift toward more personalized treatments, especially for certain populations such as pregnant patients or those with chronic infections, highlighting the importance of evidence-based, individualized care.
Sessions on office-based procedures, such as lasers and deroofing, showed their potential for wider application, pushing beyond basic treatment and offering solutions that address patient-specific needs. Looking ahead, Dr Sayed is excited about the future of HS management, particularly with new biologics, developing treatments like nanobodies, and advancements in procedures, all of which will enhance patient care in increasingly diverse scenarios.
